We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Omnicell's Rising Costs Affect Bottom Line Amid Competition
Read MoreHide Full Article
On Dec 7, we issued an updated research report on Mountain View, CA-based Omnicell Inc. (OMCL - Free Report) . The stock has a Zacks Rank #5 (Strong Sell).
Over the last three months, Omnicell’s shares have been slightly above the broader industry. The stock has gained 0.2% versus the broader industry’s gain of 0.1%.
Omnicell exited third-quarter 2017 on a mixed note with earnings beating the Zacks Consensus Estimate and revenues missing the same. Also, a weak gross margin scenario is a matter of concern. We believe the company’s strategies including portfolio expansion, acquisitions and penetration into the medication adherence market to continue driving expenses. Meanwhile, costs related to the recently launched XT series have been exerting pressure on the bottom line.
Omnicell’s lowering of the upper end of the 2017 adjusted revenue guidance is reflective of the fact that the overall slump will stay to bother. A tough competitive landscape also acts as a dampener.
On a positive note, the year-over-year increase in earnings and revenues was impressive. The company witnessed balanced growth across all business lines in the quarter. We are also encouraged the company’s efforts on product innovation through Research and Development (R&D). Omnicell has of late been observed to gain consistently from a series of product launches (the latest being XT Series Automated Supply Dispensing system) and strategic partnerships.
PetMed has a long-term expected earnings growth rate of 10%. The stock has rallied roughly 89.2% over a year.
Myriad Genetics has a long-term expected earnings growth rate of 15%. The stock has gained 94.9% in a year.
Align Technologyhas a long-term expected earnings growth rate of 28.9%. The stock has gained 142% in a year.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7% and +90.2%, respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
Omnicell's Rising Costs Affect Bottom Line Amid Competition
On Dec 7, we issued an updated research report on Mountain View, CA-based Omnicell Inc. (OMCL - Free Report) . The stock has a Zacks Rank #5 (Strong Sell).
Over the last three months, Omnicell’s shares have been slightly above the broader industry. The stock has gained 0.2% versus the broader industry’s gain of 0.1%.
Omnicell, Inc. Price
Omnicell, Inc. Price | Omnicell, Inc. Quote
Omnicell exited third-quarter 2017 on a mixed note with earnings beating the Zacks Consensus Estimate and revenues missing the same. Also, a weak gross margin scenario is a matter of concern. We believe the company’s strategies including portfolio expansion, acquisitions and penetration into the medication adherence market to continue driving expenses. Meanwhile, costs related to the recently launched XT series have been exerting pressure on the bottom line.
Omnicell’s lowering of the upper end of the 2017 adjusted revenue guidance is reflective of the fact that the overall slump will stay to bother. A tough competitive landscape also acts as a dampener.
On a positive note, the year-over-year increase in earnings and revenues was impressive. The company witnessed balanced growth across all business lines in the quarter. We are also encouraged the company’s efforts on product innovation through Research and Development (R&D). Omnicell has of late been observed to gain consistently from a series of product launches (the latest being XT Series Automated Supply Dispensing system) and strategic partnerships.
Stocks to Consider
Some better-ranked medical stocks are PetMed Express, Inc. (PETS - Free Report) , Myriad Genetics, Inc. (MYGN - Free Report) and Align Technology, Inc. (ALGN - Free Report) , all sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
PetMed has a long-term expected earnings growth rate of 10%. The stock has rallied roughly 89.2% over a year.
Myriad Genetics has a long-term expected earnings growth rate of 15%. The stock has gained 94.9% in a year.
Align Technologyhas a long-term expected earnings growth rate of 28.9%. The stock has gained 142% in a year.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +18.8% from 2016 - Q1 2017, our top stock-picking screens have returned +157.0%, +128.0%, +97.8%, +94.7% and +90.2%, respectively.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - Q1 2017, the composite yearly average gain for these strategies has beaten the market more than 11X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>